Tumor-associated neutrophils and malignant progression in intraductal papillary mucinous neoplasms an opportunity for identification of high-risk disease

Annals of Surgery

Volumn 262, Issue 6, 2015, Pages 1102-1107

  Sadot, Eran ^a   Basturk, Olca ^a   Klimstra, David S ^a   Gönen, Mithat ^a   Lokshin, Anna ^b   Do, Richard Kinh Gian ^a   D'Angelica, Michael I ^a   DeMatteo, Ronald P ^a   Peter Kingham, T ^a   Jarnagin, William R ^a   Allen, Peter J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Dysplasia; Inflammation; Intraductal papillary mucinous neoplasms; Malignant progression; Neutrophils; Pancreas

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ADULT; AGED; CANCER GROWTH; CARCINOGENESIS; CONFERENCE PAPER; CYST FLUID; DISEASE MARKER; DYSPLASIA; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INTERMEDIATE RISK PATIENT; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INVASIVE CARCINOMA; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; TUMOR ASSOCIATED NEUTROPHIL; TUMOR MICROENVIRONMENT; COLLOID CARCINOMA; DISEASE COURSE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PAPILLARY CARCINOMA; PATHOLOGY; RETROSPECTIVE STUDY; STATISTICAL MODEL; VERY ELDERLY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; DISEASE PROGRESSION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEUTROPHILS; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84948709986     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001044     Document Type: Conference Paper

References (32)

1. Maitra A, Fukushima N, Takaori K, et al. Precursors to invasive pancreatic cancer. Adv Anat Pathol. 2005;12:81-91.
2. Fritz S, Fernandez-del Castillo C, Mino-Kenudson M, et al. Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma. Ann Surg. 2009;249:440-447.
3. Poultsides GA, Reddy S, Cameron JL, et al. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg. 2010;251:470-476.
4. Wasif N, Bentrem DJ, Farrell JJ, et al. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer. 2010;116:3369-3377.
5. Yopp AC, Katabi N, Janakos M, et al. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg. 2011;253:968-974.
6. Allen PJ. The management of intraductal papillary mucinous neoplasms of the pancreas. Surg Oncol Clin N Am. 2010;19:297-310.
7. Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183-197.
8. Salvia R, Fernandez-del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004;239:678-685; discussion 685-687.
9. Steele CW, Jamieson NB, Evans TR, et al. Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer. 2013;108:997-1003.
10. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71:2411-2416.
11. Reid MD, Basturk O, Thirabanjasak D, et al. Tumor-infiltrating neutrophils in pancreatic neoplasia. Mod Pathol. 2011;24:1612-1619.
12. Maker AV, Katabi N, Qin LX, et al. Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2011;17:1502-1508.
13. Brand RE, Nolen BM, Zeh HJ, et al. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res. 2011;17:805-816.
14. Allen PJ, Qin LX, Tang L, et al. Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm. Ann Surg. 2009;250:754-760.
15. Balcom IJ, Fernandez-Del Castillo C, Warshaw AL. Cystic lesionsinthe pancreas: when to watch, when to resect. Curr Gastroenterol Rep. 2000;2:152-158.
16. Spinelli KS, Fromwiller TE, Daniel RA, et al. Cystic pancreatic neoplasms: observe or operate. Ann Surg. 2004;239:651-657; discussion 657-659.
17. Lafemina J, Katabi N, Klimstra D, et al. Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation. Ann Surg Oncol. 2013;20:440-447.
18. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17-32.
19. Gaujoux S, Brennan MF, Gonen M, et al. Cystic lesions of the pancreas: changes in the presentation and management of 1, 424 patients at a single institution over a 15-year time period. J Am Coll Surg. 2011;212:590-600; discussion 600-603.
20. Partyka K, McDonald M, Maupin KA, et al. Comparison of surgical and endoscopic sample collection for pancreatic cyst fluid biomarker identification. J Proteome Res. 2012;11:2904-2911.
21. Maker AV, Katabi N, Gonen M, et al. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol. 2011;18:199-206.
22. Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA. 2011;108:21188-21193.
23. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3:92ra66.
24. Lubezky N, Loewenstein S, Ben-Haim M, et al. MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas. Surgery. 2013;153:663-672.
25. Kang MJ, Jang JY, Kim SJ, et al. Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol. 2011;9:87-93.
26. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mono-nuclear cells. J Immunol. 2010;185:2273-2284.
27. Trellakis S, Farjah H, Bruderek K, et al. Peripheral blood neutrophil gra-nulocytes from patients with head and neck squamous cell carcinoma functionally differ from their counterparts in healthy donors. Int J Immunopathol Pharmacol. 2011;24:683-693.
28. Dumitru CA, Gholaman H, Trellakis S, et al. Tumor-derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation. Int J Cancer. 2011;129:859-869.
29. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
30. Acuff HB, Carter KJ, Fingleton B, et al. Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Res. 2006;66:259-266.
31. Masson V, de la Ballina LR, Munaut C, et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant kerati-nocytes. FA S E B J. 2005;19:234-236.
32. Correa-Gallego C, Do R, Lafemina J, et al. Predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: development of a preoperative nomogram. Ann Surg Oncol. 2013; 20:4348-4355.